To examine a series of candidate markers for urological chronic pelvic pain syndrome (UCPPS), selected based on their proposed involvement in underlying biological processes so as to provide new insights into pathophysiology and suggest targets for expanded clinical and mechanistic studies.
Objective
To examine a series of candidate markers for urological chronic pelvic pain syndrome (UCPPS), selected based on their proposed involvement in underlying biological processes so as to provide new insights into pathophysiology and suggest targets for expanded clinical and mechanistic studies.
Methods
Baseline urine samples from Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network study participants with UCPPS (n = 259), positive controls (PCs; chronic pain without pelvic pain, n = 107) and healthy controls (HCs, n = 125) were analysed for the presence of proteins that are suggested in the literature to be associated with UCPPS. Matrix metalloproteinase (MMP)-2, MMP-9, MMP-9/neutrophil gelatinase-associated lipocalin (NGAL) complex (also known as Lipocalin 2), vascular endothelial growth factor (VEGF), VEGF receptor 1 (VEGF-R1) and NGAL were assayed and quantitated using mono-specific enzyme-linked immunosorbent assays for each protein. Log-transformed concentration (pg/mL or ng/mL) and concentration normalized to total protein (pg/ lg) values were compared among the UCPPS, PC and HC groups within sex using the Student's t-test, with P values adjusted for multiple comparisons. Multivariable logistic regression and receiver-operating characteristic curves assessed the utility of the biomarkers in distinguishing participants with UCPPS and control participants. Associations of protein with symptom severity were assessed by linear regression.
Results
Significantly higher normalized concentrations (pg/lg) of VEGF, VEGF-R1 and MMP-9 in men and VEGF concentration (pg/mL) in women were associated with UCPPS vs HC. These proteins provided only marginal discrimination between UCPPS participants and HCs. In men with UCCPS, pain severity was significantly positively associated with concentrations of MMP-9 and MMP-9/NGAL complex, and urinary severity was significantly positively associated with MMP-9, MMP-9/NGAL complex and VEGF-R1. In women with UCPPS, pain and urinary symptom severity were associated with increased normalized concentrations of MMP-9/NGAL complex, while pain severity alone was associated with increased normalized concentrations of VEGF, and urinary severity alone was associated with increased normalized concentrations of MMP-2. Pain severity in women with UCPPS was significantly positively associated with concentrations of all biomarkers except NGAL, and urinary severity with all concentrations except VEGF-R1.
Conclusion
Altered levels of MMP-9, MMP-9/NGAL complex and VEGF-R1 in men, and all biomarkers in women, were
Introduction
The idiopathic nature of urological chronic pelvic pain syndrome (UCPPS), which encompasses interstitial cystitis (IC)/bladder pain syndrome (BPS) and chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS), has prompted an intense search for clinical biomarkers. Identification of clinically relevant, validated biological markers of UCPPS has great potential to inform our understanding of the pathophysiology, development and progression of UCPPS, and ultimately clinical management. To date, the cause of this syndrome is unknown and there is no ability to determine who is at risk of progression or who will respond to specific therapy. Accurate non-invasive tests, based on objective, specific and definable levels of validated biomarkers, are essential to improve and standardize clinical guidelines and for more targeted management strategies based on patient profiles.
The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), and represents a comprehensive approach to the study of UCPPS [1, 2] . A major goal of this initiative is to better understand pathophysiology and identify potential therapeutic targets. In the present MAPP network study, we have utilized a biologically driven, candidate biomarker discovery strategy, grounded in the basic biochemistry and physiology of this syndrome, to evaluate candidate non-invasive biomarkers of UCPPS.
Reviews of the literature have shown a number of candidate protein biomarker targets. Increased vascular endothelial growth factor (VEGF) levels have been detected in bladder biopsy samples from patients with IC compared with controls, with levels correlating with pain severity [3, 4] . Previous studies also suggest an important connection between neovascularization and IC, in that new blood vessels in biopsy samples of patients with IC showed significantly lower levels of pericyte coverage of the nascent endothelium, evidence consistent with the known association between high levels of VEGF and immature vessel formation [3] . Moreover, VEGF, originally discovered as vascular permeability factor (VPF) [5, 6] , is the most potent endogenous vascular permeability factor and may mediate the dysregulated vascular permeability postulated to be important in UCPPS [7] [8] [9] . Given these associations, we chose to include VEGF and VEGF receptor 1 (VEGF-R1), as biomarker candidates.
Inflammation has been suggested to be an underlying pathophysiological mechanism in UCPPS [10] , and increased concentrations of pro-inflammatory cytokines (IL-1b, TNF-a, IL-8) have been reported in patients with UCPPS as compared with controls [11, 12] . In this respect, matrix metalloproteinases (MMPs) are of particular interest. Originally thought to be associated exclusively with tissue remodelling and destruction, it is now widely appreciated that MMPs play a role in a variety of biological processes including cytokine and growth factor release, tumour growth and progression, angiogenesis and a number of inflammatory conditions [13] [14] [15] [16] [17] . During the inflammatory response, MMPs and their complexes are released from connective tissue cells in response to pro-inflammatory cytokines. Upregulation of MMP activity results in the recruitment of pro-inflammatory cells to the site of tissue injury. MMPs have also been implicated in the regulation of the immune response because of their ability to cleave inflammatory mediators and stimulate the clearance of inflammatory cells [18] [19] [20] [21] . Given that MMPs may play an important role in UCPPS as a function of the inflammatory phenotype, abnormal vasculature and the dysregulation of extracellular matrix turnover present in this and other potentially related diseases, we included these proteins in the present study.
Neutrophil gelatinase-associated lipocalin (NGAL), also known as Lipocalin 2 (Lcn2), is upregulated in numerous chronic and acute inflammatory conditions, including chronic kidney disease, ulcerative colitis and myocardial infarction [22, 23] . There exists an intricate interplay between NGAL and other inflammatory cytokines as well, such that NGAL upregulation can be triggered by multiple inflammatory cytokines, including TNF-a, IL-1b and IL-17 [22, 23] . Moreover, NGAL itself is a modulator of the levels of other inflammatory cytokines, as well as of the behaviour of inflammatory leukocytes [24] [25] [26] . In our laboratory, we have demonstrated that NGAL is a significant stimulator of VEGF levels in breast tumour cells and can also independently induce the epithelial to mesenchymal transition in breast cancer, as well as being a non-invasive biomarker of this disease [27] [28] [29] . NGAL can also form a complex with MMP-9, representing a distinct protein complex referred to as MMP-9/NGAL complex. We have previously shown that when NGAL complexes with MMP-9, it protects MMP-9 from degradation, preserving its enzyme activity [16, 30] . The MMP-9/NGAL complex has also been detected in urine samples from patients with various diseases. Based on these findings, we chose to measure NGAL as well as MMP-9/ NGAL complex in the urine of individuals with UCPPS and to correlate them with clinical symptoms.
In the present paper, we report sex-specific comparisons of candidate biomarkers among UCPPS and control cohorts to gain new insights into the underlying pathophysiology of UCPPS. In addition, associations of biomarkers with symptom severity within the UCPPS cohort were examined. We anticipate that the identified biological markers may serve as potential candidates for further clinical evaluation, including in the development of new treatment strategies directed toward novel targets, as objective measures for patient classification schemes, and evaluation of clinical outcomes, as well as further characterization of the underlying mechanism of UCPPS.
Materials and Methods
Urine Collection, Storage, Shipping Biological specimens collected in the Trans-MAPP Epidemiology/Phenotyping Study (EPS) [2] included urine collected at baseline visits. Clean-catch midstream urine was collected using alcohol-free Triad Medical-Benzalkonium chloride antiseptic towelettes (Allegro Medical, Mesa, AZ, USA) [2] . After collection, the urine was immediately frozen at À80°C and shipped to the MAPP Network Tissue Analysis and Technology Core for centralized processing, where it was then divided into 3 mL aliquots and stored at À80°C for further analysis. All specimens were de-identified to allow for blinded testing [2] . Documentation of sample origin, acquisition, transportation, processing and storage was tracked and recorded for each sample for quality assurance and quality control purposes.
Protein Assays
Urine samples were thawed, aliquoted and assayed as below. Remaining samples at the time of aliquoting were then stored at À80°C. Total protein concentration was determined using the Bradford method, with bovine serum albumin as the standard. Samples were read on a DU 640 spectrophotometer (Beckman Coulter, Brea, CA, USA).
Enzyme-Linked Immunosorbent Assay (ELISA)
Monospecific ELISAs (Quantikine; R&D Systems, Inc., Minneapolis, MN, USA) for human MMP-2, MMP-9, MMP-9/NGAL complex, NGAL, VEGF and VEGF-R1 were performed according to the manufacturer's instructions. All analyses were conducted in duplicate in a double-blinded manner, as previously reported [27, 29, [31] [32] [33] .
Study Population
The Trans-MAPP EPS enrolled men and women in three cohorts: (i) UCPPS participants; (ii) positive controls (PCs); and (iii) healthy controls (HCs) [1, 2] . UCPPS participants were defined by a non-zero response on a pelvic pain scale. PCs were defined by the presence of a non-urological associated syndrome (NUAS; fibromyalgia, chronic fatigue syndrome and/or irritable bowel syndrome), and HCs were defined by the absence of both UCPPS and other chronic pain conditions. Detailed inclusion and exclusion criteria have been described previously [2] . Stratified random sampling was used to select participants for this substudy. UCPPS participants with the most severe urological pain and urinary symptoms, as well as HCs and PCs with the least severe symptoms, were more likely to be selected to maximize the likelihood of detecting differences between UCPPS and control cohorts. Sampling was conducted within sex, and severity was determined by the sum of the Genitourinary Pain Index (GUPI) [34] pain and urinary subscores, which were categorized as mild (<13), moderate (≥13 and <23), or severe (≥23 to a maximum of 33) for selection. Demographic data were collected, and additional clinical characteristics were assessed using the RAND Interstitial Cystitis Epidemiology Study criteria [35] , the Brief Pain Inventory short form [36] , and the Interstitial Cystitis Symptom Index (ICSI) [37] . For analyses of associations of symptom severity with candidate proteins, GUPI pain and urinary subscores and items of the ICSI are reflected in two primary symptom constructs, pain severity and urinary severity [38] .
Statistical Analyses
Duplicate values of candidate proteins were evaluated for quality prior to analysis. Reliability analyses were conducted using Bland-Altman plots, coefficients of variation (CVs) and intraclass correlation coefficients (ICCs). Undetectable concentration values reported as zero were imputed with half the limit of detection (LOD), and values above the maximum detectable limit (MDL) were removed (n = 11). Unlike values below the LOD, which we know lie between 0 and the LOD, it cannot be assumed that values above the MDL are indeed that large. Values below the LOD but >0 remained as measured. Results of reliability analyses, LODs and MDLs are provided in Tables S1 and S2. and protein excretion. Concentrations ('classic concentration', ng/mL or pg/mL) and concentration normalized to total protein ('normalized concentration', pg/lg) were then logtransformed. Candidate biomarker levels were compared within sex using Student's t-test. We compared the UCPPS and HC groups to assess markers of illness and pain and the UCPPS and PC groups to identify markers unique to UCPPS. Markers that differed significantly between the UCPPS and respective controls in univariable analysis after accounting for multiple testing were entered into a multivariable logistic regression with UCPPS vs HC or UCPPS vs PC as the outcome. Corresponding receiver-operating characteristic (ROC) curves were generated. Models did not include any variables beyond the indicated proteins. We accounted for multiple testing by controlling the false discovery rate (FDR) [39] , a more powerful alternative to standard Bonferroni correction. The FDR is a generalization of type I error under a single hypothesis test to multiple hypothesis tests. This method of adjusting for multiple testing considers variable thresholds for the significance of ranked P values that result from a set of hypothesis tests instead of a single, stringent threshold applied to all tests. The FDR was set to 0.05, and the reference thresholds for P values for each test were determined by a formula based on the number of tests [39] . FDR adjustment for six tests of classic concentration was applied separately for tests of UCPPS vs HC and UCPPS vs PC, and similarly to seven tests of normalized concentration for each marker and additionally total protein. Locally weighted scatterplot smoothing was performed to visualize associations of classic and normalized concentration with pain and urinary severity [38] in all three cohorts. Among patients in the UCPPS group only, linear regression was used to quantify the association of pain and urinary severity with classic and normalized concentrations of candidate biomarkers, and associated markers in univariable analyses were entered into separate multivariable models for each symptom. Multivariable models again included markers significant after adjustment for multiple comparisons and did not adjust for other factors. Pearson correlation coefficients among markers were generated to evaluate the potential for multicollinearity in regression models.
The study was registered with ClinicalTrials.gov (Identifier: NCT01098279). Table 1 summarizes selected demographic data, prevalence of NUAS, and the primary urological pain and urinary severity levels of the Trans-MAPP EPS participants included and not included in these analyses (see Materials and Methods). The evaluated subset included 259 participants with UCPPS (139 women, 120 men), 125 HCs (75 women, 50 men), and 107 PCs (75 women, 32 men). Participants with UCPPS selected for this biomarker study reported longer duration of symptoms (mean [SD] 9.7 years [11.6] vs 6.6 years [8.6]; P = 0.002) and were more likely to have a NUAS than those not in the study (42.9% vs 30.9%; P = 0.014), and selected HCs and PCs had less severe urinary (HC, P < 0.001, PC, P < 0.001) and pain (HC, P = 0.003, PC, P < 0.001) symptoms than those not included. These results were expected given the sampling strategy. Further, men were overrepresented among the PC group relative to the prevalence of men among all MAPP PC participants, also by design.
Results
Quality control analyses using the duplicate values for each of these six biomarkers and total protein, resulted in CVs of 118.2% (MMP-2), 25.9% (MMP-9), 74.4% (MMP-9/NGAL complex), 26.2% (NGAL), 23.5% (VEGF), 57.3% (VEGF-R1) and 7.2% (total protein). ICCs resulting from these duplicate values were 0.837 (MMP-2), 0.990 (MMP-9), 0.972 (MMP-9/ NGAL complex), 0.971 (NGAL), 0.980 (VEGF), 0.793 (VEGF-R1), and 0.997 (total protein). Figure 1A and B display biomarker concentration (ng/mL or pg/mL) and normalized concentrations (pg/lg), respectively, by cohort and sex. Although boxplots suggest differences in median levels for some proteins among cohorts, large variability in measurements largely prevented such differences from reaching statistical significance. Nonetheless, urinary VEGF classic concentration was significantly higher in women in the UCPPS group than in the HC group (UCPPS, mean = 3.72; HCs, mean = 3.46; P = 0.008). ROC analysis suggested, however, that VEGF did not distinguish UCPPS participants from HCs (area under the curve [AUC] = 0.58, Fig. 2A ). Men with UCPPS had significantly higher levels of normalized VEGF (UCPPS, mean = 1.78; HC, mean = 0.98; P < 0.001), VEGF-R1 (UCPPS, mean = À0.33; HC, mean = À1.25; P = 0.004), and MMP-9 (UCPPS, mean = 2.16; HC, mean = 1.22; P = 0.001) than HC men. In multivariable analysis these three markers fairly distinguished UCPPS from HC (AUC = 0.68, Fig. 2B ).
Scatterplots suggested a positive association of concentration and normalized concentration with pain severity and urinary severity for several candidate proteins (e.g. MMP-9/NGAL and pain severity (Fig. 3) ; urinary severity and other candidate proteins not shown). Table 2A and B show the complete results of univariable and multivariable linear regression, respectively, of the two primary measures of UCPPS symptom severity [38] with respect to concentrations of each of the six candidate biomarkers within the UCPPS patient cohort, stratified by sex. In women with UCPPS, pain severity was significantly positively associated with concentrations of all biomarkers except NGAL (MMP-2, P = 0.011; MMP-9, P = 0.009; MMP-9/NGAL complex P < 0.001; VEGF, P < 0.001; VEGF-R1, P = 0.001), and urinary severity was significantly positively associated with concentrations of all biomarkers except VEGF-R1 in univariable analysis (MMP-2, P < 0.001; MMP-9, P = 0.001; BPS, bladder pain syndrome; HC, healthy control; PC, positive control; NUAS, non-urological associated syndrome; UCPPS, urological chronic pelvic pain syndrome. P values indicating such significant differences are shown in bold. *Denotes variables for which there was a significant difference between participants that were selected for the substudy compared to those who were not selected for the substudy in at least one participant cohort (UCPPS, HC or PC). † Participants were selected for this substudy by stratified random sampling within sex and cohort. UCPPS participants with the most severe urologic pain and urinary symptoms and HC and PC with the least severe symptoms were more likely to be selected to maximize the likelihood of detecting differences between UCPPS and control cohorts. ‡
Comparison of race between included and not included subjects was based on a 7-level race variable within the categories of white, black, Asian, multi-race, native Hawaiian, other, and unknown. White and black are shown for brevity. § Defined as chronic fatigue syndrome, irritable bowel sydrome, or fibromyalgia. MMP-9/NGAL, P < 0.001; NGAL, P = 0.015, VEGF, P < 0.001). After adjustment for other markers in multivariable analysis, concentrations of MMP-9/NGAL complex, VEGF and VEGF-R1 remained significantly positively associated with pain severity (MMP-9/NGAL complex, P = 0.001; VEGF, P = 0.017; VEGF-R1, P = 0.009), and only MMP-9/NGAL complex was significantly positively associated with urinary severity in women (P = 0.021). In men pain severity was significantly positively associated with the classic concentration of MMP-9 (P < 0.001) and MMP-9/ NGAL complex (P < 0.001), and urinary severity was significantly positively associated with the classic concentrations of MMP-9 (P < 0.001), MMP-9/NGAL complex (P < 0.001), and VEGF-R1 (P = 0.011; Table 2A ). In multivariable analysis none of these markers were associated with pain or urinary severity in men, which was likely attributable in part to the apparent collinearity among markers (Table 2B , q = 0.68 MMP-9 and MMP-9/NGAL complex; q = 0.16 MMP-9 and VEGF-R1; q=0.22 MMP-9/ NGAL complex and VEGF-R1 among men with UCPPS). Table 3A and B show analogous regression analyses for normalized concentrations (pg/lg). In women, pain and urinary symptom severity at baseline were each significantly positively associated with MMP-9/NGAL complex (P < 0.001). Further, increased MMP-2 and VEGF were significantly associated with greater urinary (P = 0.007) and pain severity (P = 0.013), respectively. In multivariable analysis MMP-9/NGAL complex remained significantly positively associated with pain severity in women (P < 0.001). Similarly, in the multivariable model for urinary severity in women, MMP-9/NGAL complex was significantly associated with symptom severity (P < 0.001). In men in the UCPPS group, no significant correlates of pain and urinary severity were found among normalized concentration levels of candidate biomarkers in univariable analysis, however, total urinary protein was positively associated with pain severity (P = 0.004).
Discussion
There is a lack of understanding of the aetiology and risk factors of UCPPS, and diagnosis still relies primarily on patient-reported symptoms [1] . It was previously believed that the symptoms of UCPPS were primarily seen in women; however, emerging data from the MAPP Network has shown that a large percentage of men with pelvic pain also have similar bladder symptoms [40] . Unfortunately, to date, patient therapies are generally ineffective [1] .
To identify non-invasive protein biomarkers for UCPPS that may inform underlying pathophysiology and provide targets for further clinical evaluation and hypothesis testing, the extensive resources and expertise of the MAPP Network have been leveraged to perform the largest UCPPS non-invasive biomarker analysis to date involving biological samples from over 491 individuals. Ultimately, identification and subsequent validation of such non-invasive, unbiased and accurate biomarkers may aid in identifying the presence of this syndrome, reveal clinically relevant patient sub-groups, monitor disease progression and therapeutic efficacy, predict flares, and objectively assess hallmarks of this syndrome, such as pain severity, urinary severity and other clinical manifestations. The results of the present MAPP Network biomarker study provide important insights for addressing such long-term goals through demonstrating that men with UCPPS had significantly higher normalized protein concentration of VEGF, VEGF-R1, and MMP-9 than men in the HC group. Furthermore, women with UCPPS had significantly higher concentrations of VEGF than women in the HC group. Additionally, pain and urinary symptoms were found to be positively associated with the MMP9/NGAL complex in women.
While the underlying mechanisms of UCPPS are not understood, inflammation, abnormal vascular activation, fibrosis and extracellular matrix remodeling have all been suggested to be contributing factors. Increased levels of urinary VEGF, as well as MMP-9, detected in UCPPS may reflect the upregulation of these pathways in patients. For instance, VEGF is known to regulate endothelial activation via upregulation of MMP-2 and MMP-9 in several cell types. MMP-2, in turn, may regulate VEGF expression on a transcriptional level via an integrin/PI3-kinase-dependent pathway [41] . Elevated VEGF levels have been reported in IC/BPS and VEGF levels were reduced after onabotulinumtoxinA injections and hydrodistention, suggesting that VEGF may contribute to the pathogenesis [42] . During angiogenesis, endothelial cells are guided into a vascular area by macromolecules such as VEGF. VEGF binds and activates two tyrosine kinase receptors (VEGF-R1 and VEGF-R2) and plays a role in migration of inflammatory cells and inflammation-induced lymphangiogenesis and angiogenesis [43] . Of importance in UCPPS may be the relationship of VEGF to hypoxia and ischaemia, a stimulus for angiogenesis [44, 45] . A relative ischaemia in the bladder of patients with IC/BPS during filling compared with controls has been reported [46] and the density of blood vessels in the bladder subepithelium of patients with IC/BPS is decreased [47] . In parallel to UCPPS in humans, animal models of chronic bladder ischaemia from partial bladder outlet obstruction results in increased VEGF expression [48] . Bladder epithelial cells taken from patients with overactive bladder symptoms (urinary frequency and urgency), as opposed to asymptomatic patients, respond to stretch stimuli by a 1.5-fold increase in hypoxia-inducible factors (HIF) 1a and 2a and a greater than 3-fold increase in VEGF [49] . Similarly, expression of HIF-1a and VEGF are increased in the umbrella cells of patients with IC/BPS. Finally, macrophages stimulated in low oxygen environment also secrete soluble VEGF-R1 [50] . Identifying the factors that contribute to hypoxia/ischaemia in UCPPS could reveal potential therapeutic targets.
In a murine stress model, in addition to VEGF release, bladder vascular permeability was also increased [51] . This relationship may explain the association of worsening symptoms with stress in patients with IC/BPS [52, 53] . Corticotropin-releasing hormone (CRH) stimulates mast cells to release newly synthesized VEGF which causes vasodilation [54] . The effect is mediated through CRH receptor 2 (CRH-R2) [51] and elevated VEGF levels may explain this association. In men, receptors for VEGF are present not only on endothelial cells, but also in prostate cancer and glandular and basal cells in benign prostatic hyperplasia tissue specimens [53] [54] [55] [56] . In prostate cancer cell lines, inflammation results in increased levels of MMP-9 [57] . VEGF is also an immunosuppressive cytokine [58, 59] .
In addition to roles in inflammation and angiogenesis, VEGF-R1 and MMP-9 are implicated in pain regulation. VEGF-R1 contributes to modulating the response to VEGF-R2 [58] and has recently been reported to influence pain. In mouse models, injection of VEGFA produces no spontaneous pain response, but animals develop significant hypersensitivity to graded von Frey filaments and noxious heat stimuli. This response was blocked by neutralizing antibodies to VEGF-R1 but not by antibodies against VEGF-R2. Recently, it has been reported that ligands of the VEGF family can augment pain sensitivity through selective activation of VEGF-R1 expressed in sensory neurons in human cancer and mouse models [60] . In these studies, systemic blockade of VEGF-R1 prevented tumour-induced nerve remodelling and reduced cancer pain, suggesting that the VEGF/VEGF-R1 targeting by antiangiogenic therapies could provide a palliative effect in these models [60] .
MMP-9 plays a role in regulating the acute phase of neuropathic pain. MMP-2 is constitutively expressed in many tissues, whereas MMP-9 is inducible [61] . After sciatic nerve ligation, MMP-9 was induced in <1 day and the inhibition of MMP-9 attenuated neuropathic pain at day 1 [62] . The mechanism of MMP-9 sensitization is through activation of IL-1b and microglia [61] . Elevated MMP-9 levels could reflect ongoing acute neurogenic inflammation.
Another possible contributing factor is the presence of microorganisms. The NIH-sponsored Chronic Prostatitis Collaborative Research Network found that significant bacteria were present in men with CP/CPPS but also in asymptomatic controls [63] . Although prior history of urinary tract infection (UTI) is more common in women with IC/ PBS from childhood [64] , bacteria are not usually found in the bladder [65] . In the MAPP study, in women with IC/PBS, it was shown that Gram-negative bacteria bound the TLR-4 receptor and the response to TLR-4 stimulation correlated with pain [66] . Exposure of prostate epithelial cells to LPS, on the outer membrane of Gram-negative bacteria, resulted in TLR-4-mediated release of both TGFb 1 and VEGF through activation of NF-jB [67] . Taken together, specific bacterial stimulation in the proper setting could contribute to increased levels of VEGF, regardless of gender.
In the present study, women had increased urinary MMP-9/ NGAL complex in correlation with pain and urinary symptoms. The finding of elevated MMP-9/NGAL complex suggests a possible link to bacterial infection. NGAL is rapidly and locally produced in the urinary tract by TLR receptors in response to bacterial exposure [68] . NGAL is involved in protection from bacterial infection by competing for iron with the bacteria and selecting for bacteria, with alternative chemistry of siderophores used for iron acquisition [69] . A recurring theme in patients with IC/BPS is a history of UTI that was treated, but had persistence of symptoms including pain. Elevated MMP-9/NGAL may signal bacterial involvement in pain and urinary symptom development. NGAL may also be a marker for ongoing inflammation and perhaps apoptosis.
Interestingly, our present analyses demonstrated variability in the utility of particular protein markers, depending on whether concentration values or concentration normalized to total protein values were used. Both concentration and normalized concentration values were analysed because particular protein values may be independent of overall total protein concentration and, therefore, when normalized, their ability to discriminate is lost. A limitation of the present study is the variation of duplicate measurements. CVs of ≤20% are desirable for duplicate laboratory values, and for MMP-2, MMP-9/NGAL complex, and VEGF-R1 CVs exceeded 50%, while MMP-9, NGAL and VEGF had CVs of 25.9%, 26.2%, and 23.5%, respectively. Normalized concentrations of MMP-9, VEGF and VEGF-R1 distinguished men with UCPPS from men in the HC group, but only total protein in the univariate analysis of normalized concentrations and symptom severity was associated with pain severity in men with UCPPS (Table 3A) . Elevated levels of total urinary protein may be a reflection of more concentrated urine samples, possibly as a result of decreased fluid intake to limit painful and frequent voiding. Specifically in men, total urinary protein may also reflect additional prostatic secretions that contribute to overall urinary protein.
What remains unclear in most urinary biomarker studies, is whether a particular marker is a reflection of the local (bladder or prostate) vs overall systemic changes, or a combination. This lack of specificity may contribute to the variability associated with total urinary protein normalization because total urinary protein can also change based on local injury or inflammation or hydration status. While not all patients with UCPPS have inflammation, these results support the convergence of inflammation, neuropathic pain and infection in UCPPS. Indeed, previous findings from the MAPP Network on the role of the TLR4 receptor response support these relationships [70] .
The non-invasive nature of these biomarkers would allow for frequent and economical testing in a variety of settings and research studies, and ultimately in a clinical setting if warranted. In addition to their potential to provide insights into underlying disease mechanisms, these biomarkers may potentially prove useful as targets for development of novel interventions, pending future evaluation. Indeed, US Food and Drug Administration-approved drugs that target some of these proteins, such as VEGF, are currently in clinical use [58] . Such markers, once sufficiently validated, may provide objective correlates to patient-reported symptoms and enhance strategies for multiplexing diverse phenotypic information to predict symptom progression and response to therapy for UCPPS patient sub-groups. Ongoing characterizations of these and other biomarkers are focused on validation and further assessment of relationships with clinical symptoms in a longitudinal study design.
